Why WAKIX

Different mechanism of action
Not a controlled substance
Evaluated in multiple clinical studies and FDA approved in 2019
Treats both excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy
Established safety and tolerability profile in clinical studies
Strong recommendation for the treatment of narcolepsy in adults in the American Academy of Sleep Medicine (AASM) Clinical Practice Guideline* (clinically significant improvement in EDS and cataplexy)1
*Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine.